Challenges remain regarding the therapeutic inhibition of CXCR1/2, raising two important questions: (1) Do we need to inhibit both CXCR1 and CXCR2 in prostate cancer to see a therapeutic benefit? This evidence concerns the gene CXCR2 and prostate carcinoma.